Table 1.
Demographic details
| Demographics | Neonates (CGA) | Infants and children | |||||
|---|---|---|---|---|---|---|---|
| <29 w | 29–≤35 w | 35–≤44 w | Total | 29 d–23 mo | 2–18 y | Total | |
| No. of courses, n (%) | 6 (5%) | 13 (10%) | 34 (27%) | 53 (42%) | 41 (33%) | 32 (25%) | 73 (58%) |
| CGA, median (range) | 26.5 (25.3–28.5) | 31.6 (29.2–34.4) | 40.4 (35.3–43.4) | 38.1 (25.3–43.4) | 6 m (29 d–23 mo) | 9 y 5 mo (25 mo–16 y 3 mo) | 1 y 4 mo (29 d–16 y 3 mo) |
| Vancomycin therapy, TDM and toxicity | |||||||
| Duration of vancomycin course, median (range) | 6 d (2–11 d) | 5 d (2–12 d) | 4 d (1–42 d) | 5 d (1–42 d) | 5 d (1–53 d) | 3 d (1–23 d) | 4 d (1–53 d) |
| Target trough attained at any stage during the course, n (%) | 3 (50%) | 10 (77%) | 29 (85%) | 42 (79%) | 31 (76%) | 21 (66%) | 52 (71%) |
| Number of dose adjustments, median (range) | 2 (0–3) | 1 (0–3) | 1 (0–5) | 1 (0–5) | 1 (0–7) | 1 (0–9) | 1 (0–9) |
| Vancomycin‐attributable nephrotoxicity, n (%) | 1 (17%) | 0 (0%) | 2 (6%) | 3 (6%) | 3 (7%) | 4 (12%) | 7 (10%) |
CGA, corrected gestational age; w, weeks; TDM, therapeutic drug monitoring.